...
首页> 外文期刊>Clinical and experimental pharmacology & physiology >Effect of statin therapy on plasma high-density lipoprotein-cholesterol levels is modified by paraoxonase 1 in Chinese patients with coronary heart disease.
【24h】

Effect of statin therapy on plasma high-density lipoprotein-cholesterol levels is modified by paraoxonase 1 in Chinese patients with coronary heart disease.

机译:他汀类药物治疗对中国冠心病患者血浆高密度脂蛋白胆固醇水平的影响被对氧磷酶1修饰。

获取原文
获取原文并翻译 | 示例

摘要

1. We sought to determine the effects of Q192R polymorphism of paraoxonase 1 (PON1) gene on plasma high-density lipoprotein-cholesterol (HDL-C) levels and the response to statin therapy in Chinese patients with coronary heart disease (CHD). 2. Two hundred and thirty-six patients with CHD were treated with simvastatin 20 mg/day. Fasting serum lipids were determined before and after 12 weeks of treatment. 3. No significant differences were detected among the PON1 Q192R polymorphism with respect to plasma lipids. In addition, the effects of simvastatin to increase HDL-C levels were significantly greater in patients with the RR genotype compared with patients with the QR or RR genotypes (P 0.05). 4. We conclude that the Q192R polymorphism of PON1 significantly modulates the HDL-C response to simvastatin in Chinese patients with CHD.
机译:1.我们试图确定中国人冠心病(CHD)患者对氧磷合酶1(PON1)基因Q192R多态性对血浆高密度脂蛋白胆固醇(HDL-C)水平的影响以及他汀类药物治疗的反应。 2. 236例冠心病患者接受辛伐他汀20 mg /天治疗。在治疗12周之前和之后测定空腹血清脂质。 3. PON1 Q192R多态性在血浆脂质方面未发现显着差异。此外,与具有QR或RR基因型的患者相比,具有RR基因型的患者中辛伐他汀提高HDL-C水平的作用明显更大(P <0.05)。 4.我们得出结论,中国CHD患者中PON1的Q192R多态性显着调节了对辛伐他汀的HDL-C反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号